Motley Fool Wealth Management LLC Acquires 1,466 Shares of ICON Public Limited (NASDAQ:ICLR)

Motley Fool Wealth Management LLC grew its stake in shares of ICON Public Limited (NASDAQ:ICLR) by 2.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 64,038 shares of the medical research company’s stock after purchasing an additional 1,466 shares during the quarter. Motley Fool Wealth Management LLC’s holdings in ICON Public were worth $13,342,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Whittier Trust Co. of Nevada Inc. grew its position in ICON Public by 128.2% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 1,166 shares of the medical research company’s stock worth $245,000 after acquiring an additional 655 shares during the last quarter. Whittier Trust Co. grew its holdings in shares of ICON Public by 17.8% in the fourth quarter. Whittier Trust Co. now owns 4,736 shares of the medical research company’s stock worth $993,000 after purchasing an additional 716 shares during the last quarter. Horizon Investments LLC increased its stake in shares of ICON Public by 534.0% in the fourth quarter. Horizon Investments LLC now owns 653 shares of the medical research company’s stock worth $137,000 after buying an additional 550 shares during the period. Natixis Advisors LLC raised its holdings in ICON Public by 6.7% during the 4th quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company’s stock valued at $37,279,000 after buying an additional 11,177 shares during the last quarter. Finally, Private Trust Co. NA boosted its position in ICON Public by 48.8% during the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock valued at $52,000 after buying an additional 82 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.

ICON Public Trading Down 2.9 %

Shares of NASDAQ ICLR opened at $179.02 on Wednesday. ICON Public Limited has a 1 year low of $174.93 and a 1 year high of $347.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34. The firm has a 50-day moving average of $191.67 and a 200 day moving average of $223.96. The stock has a market cap of $14.46 billion, a P/E ratio of 18.78, a price-to-earnings-growth ratio of 1.86 and a beta of 1.21.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The firm had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.04 billion. As a group, sell-side analysts expect that ICON Public Limited will post 13.38 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on ICLR. William Blair restated an “outperform” rating on shares of ICON Public in a research report on Tuesday, January 14th. Truist Financial reduced their price target on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Barclays dropped their price objective on ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a report on Friday, February 21st. The Goldman Sachs Group lowered ICON Public from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $250.00 to $200.00 in a research report on Friday, March 21st. Finally, Royal Bank of Canada restated an “outperform” rating and set a $263.00 target price on shares of ICON Public in a report on Wednesday, January 15th. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, ICON Public presently has a consensus rating of “Moderate Buy” and an average price target of $272.50.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.